Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$4.76−0.41 (-7.93%)
Close on Nov 19, 2026Market cap $257.83MP/E –Yield –
Eikon Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$93.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$87.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$109.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$71.38M | – |
See a number that looks wrong?